This article is for informational purposes only and does not constitute medical advice. These are prescription medications — discuss with a registered medical practitioner.
The comparison of tirzepatide vs semaglutide has become one of the defining clinical questions in obesity medicine — and in Australia, where TGA approval status and PBS access determine what is actually reachable for most patients, the stakes are higher than a simple efficacy debate. Both drugs represent a genuine step change in pharmacological weight loss. But they work through different mechanisms, produce different trial outcomes, carry distinct cost profiles, and sit in very different places on the PBS.
Tirzepatide is marketed as Mounjaro (for type 2 diabetes) by Eli Lilly. Semaglutide is marketed as Ozempic (for type 2 diabetes) and Wegovy (for obesity) by Novo Nordisk. Both are once-weekly injectables that produce substantial weight loss — but the mechanisms diverge meaningfully, and so do the clinical outcomes and the cost to an Australian patient.
This article covers how each drug works, what the trial data shows, Australian TGA and PBS status as of May 2026, cost comparisons in AUD, and the clinical considerations that point toward one or the other.
Semaglutide mimics glucagon-like peptide-1 (GLP-1), a gut hormone released after eating. GLP-1 receptors are found in the pancreas (stimulating glucose-dependent insulin secretion), the stomach (slowing gastric emptying), and the brain — particularly in hypothalamic appetite-control regions and brainstem satiety circuits. Semaglutide binds these receptors with high affinity and a half-life of approximately one week, producing sustained hunger reduction, earlier satiety, and slower gastric emptying. The weight loss is neurobiologically driven, not willpower dependent.
Understanding how GLP-1 receptor agonists interact with insulin resistance and metabolic signalling is central to appreciating why these drugs produce such consistent results across populations.
Tirzepatide is a single peptide that activates both GLP-1 receptors and glucose-dependent insulinotropic polypeptide (GIP) receptors simultaneously. GIP is the other major incretin hormone, released from the small intestine in response to nutrients. GIP receptor activation appears to enhance the central appetite-suppressing effects of GLP-1 signalling, directly modulates fat tissue metabolism, and may attenuate some of the nausea associated with pure GLP-1 agonism.
Critically, tirzepatide is not simply GIP and GLP-1 combined — its single molecular structure activates both receptors with a distinct pharmacological profile that produces synergistic rather than merely additive effects. This is the mechanistic basis for tirzepatide's consistently superior weight loss data.
Researchers studying GLP-1 and GIP receptor pharmacology can access GLP-1 research peptide compounds for preclinical laboratory investigation of these pathways.
The SUSTAIN programme established semaglutide's T2DM efficacy and landmark cardiovascular outcomes (SUSTAIN-6: 26% reduction in major adverse cardiovascular events). For obesity, the STEP programme is the key data set — STEP 1, the pivotal trial, enrolled 1,961 adults with obesity and no diabetes over 68 weeks on semaglutide 2.4 mg or placebo, with lifestyle counselling in both arms.
The SURMOUNT programme is the obesity-specific trial series for tirzepatide. SURMOUNT-1 enrolled 2,539 adults with obesity or overweight plus at least one comorbidity (no diabetes) over 72 weeks, randomising participants to tirzepatide 5 mg, 10 mg, or 15 mg, or placebo.
The SURPASS-2 trial provided the only direct head-to-head comparison: tirzepatide 5 mg, 10 mg, and 15 mg versus semaglutide 1 mg in adults with T2DM on metformin. Tirzepatide outperformed semaglutide at every dose for both HbA1c reduction and weight loss — tirzepatide 15 mg produced 11.2 kg average weight loss versus 5.7 kg for semaglutide 1 mg over 40 weeks. Note that SURPASS-2 used the standard 1 mg diabetes dose of semaglutide, not the 2.4 mg obesity dose; cross-trial comparisons need methodological caution, but the directional signal is consistent across all data.
| Drug | Trial | Population | Duration | Mean Weight Loss |
|---|---|---|---|---|
| Semaglutide 2.4 mg | STEP 1 | Obesity, no T2DM | 68 weeks | 14.9% body weight |
| Semaglutide 2.4 mg | STEP 2 | Obesity + T2DM | 68 weeks | 9.6% body weight |
| Semaglutide 2.4 mg | STEP 3 (+ IBT) | Obesity, no T2DM | 68 weeks | 16.0% body weight |
| Tirzepatide 15 mg | SURMOUNT-1 | Obesity, no T2DM | 72 weeks | 20.9% body weight |
| Tirzepatide 15 mg | SURMOUNT-2 | Obesity + T2DM | 72 weeks | 15.7% body weight |
SURMOUNT-1's 20.9% average weight loss is the headline number — and it is clinically substantial. At a starting weight of 100 kg, that is roughly 21 kg versus approximately 15 kg for semaglutide in STEP 1. Nearly half of tirzepatide 15 mg participants lost ≥20% of body weight; approximately one in five lost ≥25% — outcomes previously associated only with bariatric surgery.
These are group averages. Individual responses vary considerably on both drugs. STEP 3 also demonstrates that combining semaglutide with intensive behavioural therapy lifted outcomes to 16%, reinforcing that lifestyle integration matters regardless of which agent is used.
Both drugs share the same class-level gastrointestinal profile: nausea, vomiting, diarrhoea, constipation, and abdominal discomfort — all most pronounced during dose escalation and typically resolving within 4–8 weeks at a stable dose. In SURMOUNT-1, nausea occurred in approximately 31% of tirzepatide 15 mg patients, consistent with semaglutide trial rates.
Some clinicians observe that tirzepatide's nausea may be subjectively milder than semaglutide's at doses producing comparable weight loss — mechanistically attributed to GIP co-agonism moderating GLP-1-driven nausea signals. This is plausible but not yet confirmed in direct comparative trials. Both drugs are titrated slowly (semaglutide: 0.25 mg up to 2.4 mg over 16–20 weeks; tirzepatide: 2.5 mg up to 15 mg over 20+ weeks) to allow GI tolerance to develop.
Pancreatitis: A class warning applies to both. Discontinue if pancreatitis is suspected; do not restart if confirmed. Prior pancreatitis history requires careful risk-benefit discussion with a prescribing doctor.
Thyroid C-cell effects: Both carry contraindications for personal or family history of medullary thyroid carcinoma or MEN 2, based on rodent findings. No causal association has been established in humans.
Gallbladder disease: Rapid weight loss increases gallstone risk. Both drugs show higher cholelithiasis rates versus placebo in trials; the risk may be more pronounced with tirzepatide given greater weight loss magnitude.
Hypoglycaemia: Minimal risk as monotherapy or with metformin; increases with sulphonylureas or insulin in T2DM management.
There is no evidence to date that tirzepatide's dual mechanism introduces a substantially different or elevated serious adverse event profile versus semaglutide in trial populations.
Semaglutide holds two TGA registrations: Ozempic (0.5 mg, 1 mg, 2 mg) approved January 2020 for T2DM; Wegovy (2.4 mg) approved late 2023 for chronic weight management in adults with BMI ≥30 or BMI ≥27 with comorbidities. Both are available at Australian pharmacies, with Ozempic supply substantially recovered from the 2023–2024 shortage period.
Tirzepatide holds one TGA registration: Mounjaro (2.5 mg through 15 mg), approved for adults with T2DM. Mounjaro is available at Australian pharmacies on private prescription for T2DM patients, though stock availability is less consistent than Ozempic — patients may need to pre-order or check multiple pharmacies.
Zepbound (tirzepatide for obesity — the US brand name for the obesity indication) is not separately TGA-registered in Australia as of May 2026. Prescribers may and do prescribe Mounjaro off-label for weight management under Australia's general off-label prescribing rules. A TGA submission for tirzepatide in the obesity indication is anticipated, but no confirmed timeline has been announced by Eli Lilly Australia.
Ozempic is PBS-listed for T2DM. Criteria: confirmed T2DM diagnosis, inadequate glycaemic control despite lifestyle modification, prior metformin use or documented contraindication. General patient co-payment: ~$31.60/month; concession card holders: ~$7.70/month.
Wegovy for obesity has received a PBAC recommendation and is progressing toward PBS listing in 2026. Expected eligibility criteria:
Full eligibility details, including the Wegovy PBS listing timeline and projected co-payments, are covered in the dedicated article.
Mounjaro is not PBS-listed in Australia for any indication as of May 2026. All tirzepatide prescriptions — for T2DM or off-label for obesity — are filled at full private cost. A PBAC submission for T2DM is expected in due course, to be followed by an obesity submission. Until those listings occur, there is no PBS subsidy available for tirzepatide.
| Treatment | PBS Available? | Est. Monthly Cost (AUD) | Est. Annual Cost (AUD) |
|---|---|---|---|
| Ozempic — T2DM, general patient | Yes | ~$31.60 | ~$379 |
| Ozempic — T2DM, concession holder | Yes | ~$7.70 | ~$92 |
| Ozempic — off-label weight loss | No | ~$130–$160 | ~$1,560–$1,920 |
| Wegovy — obesity (PBS, once listed) | Pending 2026 | ~$31.60 projected | ~$379 projected |
| Wegovy — private | No | ~$350–$450 | ~$4,200–$5,400 |
| Mounjaro — all indications | No | ~$350–$500 | ~$4,200–$6,000 |
The cost gap is the dominant practical consideration for most Australian patients comparing tirzepatide vs semaglutide. PBS-listed Wegovy at ~$379 per year versus private Mounjaro at $4,200–$6,000 per year is a roughly tenfold difference. Major pharmacy chains such as Chemist Warehouse may offer more competitive private pricing for Mounjaro than smaller independents — worth comparing before dispensing. PBS Safety Net provisions further reduce costs for high-volume PBS users once annual thresholds are met.
Neither medication replaces lifestyle modification — both are approved as adjuncts to diet and exercise. STEP 3 illustrated this clearly: semaglutide plus intensive behavioural therapy produced 16% weight loss versus 14.9% with standard counselling alone. The same principle applies to tirzepatide.
Dietary priorities alongside either drug:
For patients exploring natural approaches that support GLP-1 signalling as a complementary strategy, evidence-based options are reviewed in that article.
Exercise: Resistance training 2–3 times weekly alongside regular aerobic activity is the most effective strategy for preserving lean mass during GLP-1-class pharmacotherapy. Meta-analyses consistently show better body composition outcomes and cardiovascular biomarker improvements when structured exercise is combined with either agent compared to pharmacotherapy alone.
By average trial weight loss, tirzepatide is stronger: 20.9% body weight in SURMOUNT-1 (tirzepatide 15 mg) versus 14.9% in STEP 1 (semaglutide 2.4 mg). In the direct SURPASS-2 head-to-head in T2DM, tirzepatide outperformed semaglutide at every dose. Individual responses vary substantially — some patients achieve excellent results on semaglutide and "stronger on average" does not mean "stronger for every individual."
Pharmacologically, yes — tirzepatide (Mounjaro) produces greater average weight loss than semaglutide (Ozempic). But "better" in Australia also involves cost and access. Mounjaro is not PBS-listed and costs $350–$500/month privately. Ozempic is PBS-listed for T2DM at ~$31.60/month, and Wegovy for obesity is approaching PBS listing at a similar projected co-payment. For many Australians, the more affordable semaglutide PBS pathway is the more sustainable long-term option — the cost-versus-efficacy trade-off is one to discuss with your prescribing doctor.
Yes, switching is clinically feasible and practised when semaglutide has not produced adequate results. There is no mandatory washout period, but prescribers typically restart tirzepatide from the lowest titration dose to allow GI tolerance to develop. Any switch should be made in consultation with your doctor — blood glucose monitoring is particularly important during the transition if you have T2DM.
Mounjaro is TGA-approved for T2DM only, but Australian law permits off-label prescribing at a doctor's clinical discretion. Prescribers can prescribe Mounjaro off-label for weight management — this would be a private script at full cost (~$350–$500/month). No PBS subsidy exists for tirzepatide as of May 2026 for any indication.
Both share the same GI side effect profile (nausea, vomiting, diarrhoea, constipation, abdominal discomfort) and the same class warnings (pancreatitis, thyroid C-cell, gallbladder). Some patients and clinicians report subjectively milder nausea with tirzepatide — attributed to GIP co-agonism potentially moderating GLP-1-driven nausea — but this is not confirmed in direct comparative trials. No evidence to date shows tirzepatide introducing substantially different or elevated serious adverse events compared to semaglutide.
No PBS listing date has been confirmed for Mounjaro as of May 2026. A PBAC submission for T2DM is expected; an obesity indication submission would follow TGA approval of that indication. Once a PBAC recommendation is granted, the standard 3–6 month timeline to pharmacy availability applies. Monitor pbs.gov.au for updates.
The clinical evidence is clear: tirzepatide produces greater average weight loss than semaglutide — approximately 21% versus 15% of body weight in obesity-specific trials, and a consistent advantage in head-to-head T2DM comparison. The dual GIP/GLP-1 mechanism is a genuine pharmacological advance.
In Australia in 2026, however, semaglutide holds an overwhelming practical advantage for qualifying patients. PBS-listed Ozempic for T2DM and the approaching PBS listing of Wegovy for obesity deliver strong, clinically meaningful efficacy at approximately $31–$380 per year for eligible patients — a cost structure that tirzepatide cannot currently match. Private Mounjaro at $4,200–$6,000 per year is viable for patients who need maximum weight loss, can sustain the cost, and are already on private prescriptions — but for most Australians, the PBS semaglutide pathway is the more realistic and sustainable option until tirzepatide reaches PBS listing.
The right choice depends on your individual clinical profile, comorbidities, treatment history, and financial situation. Both drugs are prescription-only and require ongoing medical supervision — dose titration, side effect management, and continuation criteria all need a treating doctor involved throughout. That conversation begins with a registered medical practitioner.
Information accurate as of May 2026. TGA approvals and PBS listings are subject to change — verify current status at tga.gov.au and pbs.gov.au. Trial data sourced from published SURMOUNT, STEP, SUSTAIN, and SURPASS programme publications.
Eli Lilly's orforglipron is the first non-peptide oral GLP-1 agonist with full Phase 3 data. This guide covers the ATTAIN-1 obesity trial, the ACHIEVE-1 T2D trial, weight loss versus injectable semaglutide and tirzepatide, side-effect profile, and Australian timeline implications.
A research-backed explainer on orforglipron (Foundayo) — the first oral small-molecule GLP-1 receptor agonist approved for weight loss, why no-restriction dosing matters, what the ATTAIN trials showed, and how it compares to injectables and oral semaglutide.
A detailed breakdown of the TRIUMPH-1 Phase 3 trial results for retatrutide — the triple-hormone agonist that achieved up to 28.3% mean weight loss at 80 weeks and ~30.3% in a higher-BMI subgroup at 104 weeks.